Acuson reports stable first quarter
Ultrasound vendor Acuson of Mountain View, CA, reported single-digit growth in sales for its first quarter (end-April), while net income dipped slightly. The company reported that U.S. sales remain stable, while international shipments increased 4%
Ultrasound vendor Acuson of Mountain View, CA, reported single-digit growth in sales for its first quarter (end-April), while net income dipped slightly. The company reported that U.S. sales remain stable, while international shipments increased 4% thanks to the shipment of a large order to China.
For the period, Acuson logged $119 million in sales, up 2.8% compared with $115.8 million in revenues in the first quarter of 1998. The company posted net income of $5.5 million in the quarter, compared with net income of $5.7 million in the corresponding quarter a year ago. Acusons operating income was higher this quarter than a year ago, but the companys net profit was reduced by a $1 million charge for interest expense.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
